|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Berkhof J, de Bruijne MC, Zielinski GD and
Meijer CJ: Natural history and screening model for high-risk human
papillomavirus infection, neoplasia and cervical cancer in the
Netherlands. Int J Cancer. 115:268–275. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McCredie MR, Sharples KJ, Paul C, Baranyai
J, Medley G, Jones RW and Skegg DC: Natural history of cervical
neoplasia and risk of invasive cancer in women with cervical
intraepithelial neoplasia 3: A retrospective cohort study. Lancet
Oncol. 9:425–434. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
González-Herrera L, Rodríguez-Morales P,
Gonza Lez-Losa Mdel R, Pérez-Mendoza G, Canul-Canché J,
Rosado-López I and Cetina TC: MTHFR/p53 polymorphisms as genetic
factors for cervical intraepithelial neoplasia and cervical cancer
in HPV-infected Mexican women. Int J Biol Markers. 29:e142–e149.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuglik P, Kasikova K, Smetana J, Vallova
V, Lastuvkova A, Moukova L, Cvanova M and Brozova L: Molecular
cytogenetic analyses of hTERC (3q26) and MYC (8q24) genes
amplifications in correlation with oncogenic human papillomavirus
infection in Czech patients with cervical intraepithelial neoplasia
and cervical carcinomas. Neoplasma. 62:130–139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lund AH and van Lohuizen M: RUNX: A
trilogy of cancer genes. Cancer Cell. 1:213–215. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ito Y and Miyazono K: RUNX transcription
factors as key targets of TGF-beta superfamily signaling. Curr Opin
Genet Dev. 13:43–47. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hwang KT, Han W, Bae JY, Hwang SE, Shin
HJ, Lee JE, Kim SW, Min HJ and Noh DY: Downregulation of the RUNX3
gene by promoter hypermethylation and hemizygous deletion in breast
cancer. J Korean Med Sci. 22 (Suppl):S24–S31. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li QL, Ito K, Sakakura C, Fukamachi H,
Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, et al: Causal
relationship between the loss of RUNX3 expression and gastric
cancer. Cell. 109:113–124. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Subramaniam MM, Chan JY, Yeoh KG, Quek T,
Ito K and Salto-Tellez M: Molecular pathology of RUNX3 in human
carcinogenesis. Biochim Biophys Acta. 1796:315–331. 2009.PubMed/NCBI
|
|
11
|
Xiao WH and Liu WW: Hemizygous deletion
and hypermethylation of RUNX3 gene in hepatocellular carcinoma.
World J Gastroenterol. 10:376–380. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Z, Fan P, Deng M and Zeng C: The roles
of RUNX3 in cervical cancer cells in vitro. Oncol Lett.
15:8729–8734. 2018.PubMed/NCBI
|
|
13
|
Gao F, Huang C, Lin M, Wang Z, Shen J,
Zhang H, Jiang L and Chen Q: Frequent inactivation of RUNX3 by
promoter hypermethylation and protein mislocalization in oral
squamous cell carcinomas. J Cancer Res Clin Oncol. 135:739–747.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ito K, Liu Q, Salto-Tellez M, Yano T, Tada
K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, et al: RUNX3, a
novel tumor suppressor, is frequently inactivated in gastric cancer
by protein mislocalization. Cancer Res. 65:7743–7750. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li
QL, Yang JO, Ito Y and Bae SC: RUNX3 inactivation by point
mutations and aberrant DNA methylation in bladder tumors. Cancer
Res. 65:9347–9354. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito
K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, et al: RUNX3 is
frequently inactivated by dual mechanisms of protein
mislocalization and promoter hypermethylation in breast cancer.
Cancer Res. 66:6512–6520. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kudo Y, Tsunematsu T and Takata T:
Oncogenic role of RUNX3 in head and neck cancer. J Cell Biochem.
112:387–393. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsunematsu T, Kudo Y, Iizuka S, Ogawa I,
Fujita T, Kurihara H, Abiko Y and Takata T: RUNX3 has an oncogenic
role in head and neck cancer. PLoS One. 4:e58922009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee JH, Pyon JK, Kim DW, Lee SH, Nam HS,
Kang SG, Kim CH, Lee YJ, Chun JS and Cho MK: Expression of RUNX3 in
skin cancers. Clin Exp Dermatol. 36:769–774. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Häfner N, Steinbach D, Jansen L, Diebolder
H, Dürst M and Runnebaum IB: RUNX3 and CAMK2N1 hypermethylation as
prognostic marker for epithelial ovarian cancer. INT J Cancer.
138:217–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lotem J, Levanon D, Negreanu V, Bauer O,
Hantisteanu S, Dicken J and Groner Y: Runx3 at the interface of
immunity, inflammation and cancer. Biochim Biophys Acta.
1855:131–143. 2015.PubMed/NCBI
|
|
22
|
Gao QQ, Zhou B, Yu XZ, Zeng X, Zhang Z,
Quan Y, Wang YY, Pu Y, Cheng P, Song YP, et al: RUNX3 polymorphisms
and the susceptibility to cervical cancer and cervical
intraepithelial neoplasia in Western China. Int J Clin Exp Pathol.
9:10617–10626. 2016.
|
|
23
|
Lee JW, Kim DM, Jang JW, Park TG, Song SH,
Lee YS, Chi XZ, Park IY, Hyun JW, Ito Y and Bae SC: RUNX3 regulates
cell cycle-dependent chromatin dynamics by functioning as a pioneer
factor of the restriction-point. Nat Commun. 10:18972019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dal Cin P, Fusco A, Belge G, Chiappetta G,
Fedele M, Pauwels P, Bullerdiek J and Van den Berghe H: Involvement
of the HMGI(Y) gene in a microfollicular adenoma of the thyroid.
Genes Chromosomes Cancer. 24:286–289. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Nakajima K, Tabatabai ZL, Ishii N and Dahiya R: Long Noncoding RNA
MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and
interacts with miR-205. Cancer Res. 75:1322–1331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Quan Y, Zhou B, Wang Y, Duan R, Wang K,
Gao Q, Shi S, Song Y, Zhang L and Xi M: Association between IL17
polymorphisms and risk of cervical cancer in Chinese women. Clin
Dev Immunol. 2012:258–293. 2012. View Article : Google Scholar
|
|
28
|
Walch-Rückheim B, Mavrova R, Henning M,
Vicinus B, Kim YJ, Bohle RM, Juhasz-Böss I, Solomayer EF and Smola
S: Stromal fibroblasts induce CCL20 through IL6/C/EBPβ to support
the recruitment of Th17 cells during cervical cancer progression.
Cancer Res. 75:5248–5259. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zidi S, Sghaier I, Gazouani E, Mezlini A
and Yacoubi-Loueslati B: Evaluation of Toll-like receptors 2/3/4/9
gene polymorphisms in cervical cancer evolution. Pathol Oncol Res.
22:323–330. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zidi S, Stayoussef M, Gazouani E, Mezlini
A, Yacoubi-Loueslati B and Almawi WY: Relationship of common
vascular endothelial growth factor polymorphisms and haplotypes
with the risk of cervical cancer in Tunisians. Cytokine.
74:108–112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barghout SH, Zepeda N, Vincent K, Azad AK,
Xu Z, Yang C, Steed H, Postovit LM and Fu Y: RUNX3 contributes to
carboplatin resistance in epithelial ovarian cancer cells. Gynecol
Oncol. 138:647–655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yano T, Ito K, Fukamachi H, Chi XZ, Wee
HJ, Inoue K, Ida H, Bouillet P, Strasser A, Bae SC and Ito Y: The
RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells
undergoing transforming growth factor beta-induced apoptosis. Mol
Cell Biol. 26:4474–4488. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yamamura Y, Lee WL, Inoue K, Ida H and Ito
Y: RUNX3 cooperates with FoxO3a to induce apoptosis in gastric
cancer cells. J Biol Chem. 281:5267–5276. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chi XZ, Yang JO, Lee KY, Ito K, Sakakura
C, Li QL, Kim HR, Cha EJ, Lee YH, Kaneda A, et al: RUNX3 suppresses
gastric epithelial cell growth by inducing p21(WAF1/Cip1)
expression in cooperation with transforming growth factor
{beta}-activated SMAD. Mol Cell Biol. 25:8097–8107. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Farooqi AA, Khalid S and Ahmad A:
Regulation of cell signaling pathways and miRNAs by resveratrol in
different cancers. Int J Mol Sci. 19(pii): E6522018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ito K, Lim AC, Salto-Tellez M, Motoda L,
Osato M, Chuang LS, Lee CW, Voon DC, Koo JK, Wang H, et al: RUNX3
attenuates beta-catenin/T cell factors in intestinal tumorigenesis.
Cancer Cell. 14:226–237. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nagahama Y, Ishimaru M, Osaki M, Inoue T,
Maeda A, Nakada C, Moriyama M, Sato K, Oshimura M and Ito H:
Apoptotic pathway induced by transduction of RUNX3 in the human
gastric carcinoma cell line MKN-1. Cancer Sci. 99:23–30.
2008.PubMed/NCBI
|
|
38
|
Gao J, Chen Y, Wu KC, Liu J, Zhao YQ, Pan
YL, Du R, Zheng GR, Xiong YM, Xu HL and Fan DM: RUNX3 directly
interacts with intracellular domain of Notch1 and suppresses Notch
signaling in hepatocellular carcinoma cells. Exp Cell Res.
316:149–157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Holdbrooks AT, Britain CM and Bellis SL:
ST6Gal-I sialyltransferase promotes tumor necrosis factor
(TNF)-mediated cancer cell survival via sialylation of the TNF
receptor 1 (TNFR1) death receptor. J Biol Chem. 293:1610–1622.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zidi S, Stayoussef M, Zouidi F, Benali S,
Gazouani E, Mezlini A and Yacoubi-Loueslati B: Tumor necrosis
factor alpha (−238/-308) and TNFRII–VNTR (−322) polymorphisms as
genetic biomarkers of susceptibility to develop cervical cancer
among tunisians. Pathol Oncol Res. 21:339–345. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tanaka T, Imamura T, Yoneda M, Irie A, Ogi
H, Nagata M, Yoshida R, Fukuma D, Kawahara K, Shinohara M and
Nakayama H: Enhancement of active MMP release and invasive activity
of lymph node metastatic tongue cancer cells by elevated signaling
via the TNF-α-TNFR1-NF-κB pathway and a possible involvement of
angiopoietin-like 4 in lung metastasis. Int J Oncol. 49:1377–1384.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mitchell S, Vargas J and Hoffmann A:
Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med.
8:227–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Farhan M, Wang H, Gaur U, Little PJ, Xu J
and Zheng W: foxo signaling pathways as therapeutic targets in
cancer. Int J Biol Sci. 13:815–827. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Coomans de Brachène A and Demoulin JB:
FOXO transcription factors in cancer development and therapy. Cell
Mol Life Sci. 73:1159–1172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Link W and Fernandez-Marcos PJ: FOXO
transcription factors at the interface of metabolism and cancer.
Int J Cancer. 141:2379–2391. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yadav H, Devalaraja S, Chung ST and Rane
SG: TGF-β1/Smad3 pathway targets PP2A-AMPK-FoxO1 signaling to
regulate hepatic gluconeogenesis. J Biol Chem. 292:3420–3432. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhao X, Liu Y, Du L, He L, Ni B, Hu J, Zhu
D and Chen Q: Threonine 32 (Thr32) of FoxO3 is critical for
TGF-β-induced apoptosis via Bim in hepatocarcinoma cells. Protein
Cell. 6:127–138. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu Y, Zhang G, Zou C, Zhang H, Gong Z,
Wang W, Ma G, Jiang P and Zhang W: LncRNA MT1JP suppresses gastric
cancer cell proliferation and migration through
MT1JP/MiR-214-3p/RUNX3 axis. Cell Physiol Biochem. 46:2445–2459.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang J, Zhou W, Liu Y, Liu T, Li C and
Wang L: Oncogenic role of microRNA-532-5p in human colorectal
cancer via targeting of the 5′UTR of RUNX3. Oncol Lett.
15:7215–7220. 2018.PubMed/NCBI
|
|
50
|
Xue D, Lu H, Xu HY, Zhou CX and He XZ:
Long noncoding RNA MALAT1 enhances the docetaxel resistance of
prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
J Cell Mol Med. 22:3223–3237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bai L, Wang A, Zhang Y, Xu X and Zhang X:
Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer
cells to cisplatin through inhibiting the Notch1 signaling pathway.
Exp Cell Res. 366:161–171. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fang Z, Chen W, Yuan Z, Liu X and Jiang H:
LncRNA-MALAT1 contributes to the cisplatin-resistance of lung
cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed
Pharmacother. 101:536–542. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Xiping Z, Bo C, Shifeng Y, Feijiang Y,
Hongjian Y, Qihui C and Binbin T: Roles of MALAT1 in development
and migration of triple negative and Her-2 positive breast cancer.
Oncotarget. 9:2255–2267. 2017.PubMed/NCBI
|
|
54
|
Shen F, Zheng H, Zhou L, Li W and Xu X:
Overexpression of MALAT1 contributes to cervical cancer progression
by acting as a sponge of miR-429. J Cell Physiol. 234:11219–11226.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li J, Wang W, Xia P, Wan L, Zhang L, Yu L,
Wang L, Chen X, Xiao Y and Xu C: Identification of a five-lncRNA
signature for predicting the risk of tumor recurrence in patients
with breast cancer. Int J cancer. 143:2150–2160. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jiang W, Zhan H, Jiao Y, Li S and Gao W: A
novel lncRNA-miRNA-mRNA network analysis identified the hub lncRNA
RP11-159F24.1 in the pathogenesis of papillary thyroid cancer.
Cancer Med. 7:6290–6298. 2018. View Article : Google Scholar : PubMed/NCBI
|
